2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery*
Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery*. Critical Care Medicine 2012, 40: 2805-2812. PMID: 22824930, PMCID: PMC3588582, DOI: 10.1097/ccm.0b013e31825b8be2.Peer-Reviewed Original ResearchConceptsAcute renal failureAngiotensin-converting enzyme inhibitorMineralocorticoid receptor blockadePostoperative atrial fibrillationMineralocorticoid receptor antagonistsAtrial fibrillationPlacebo groupSpironolactone groupRenal failureCardiac surgeryReceptor blockadeReceptor antagonistEnzyme inhibitorsDouble-blind placebo-controlled studyAngiotensin-converting enzyme inhibitionPrevalence of hypotensionElective cardiac surgeryPlacebo-controlled studyRenin-angiotensin systemNormal sinus rhythmEnzyme inhibitionRamipril groupSpironolactone useHospital stayPrimary endpoint
2011
The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians
Vaidya A, Sun B, Forman JP, Hopkins PN, Brown NJ, Kolatkar NS, Williams GH, Williams JS. The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clinical Endocrinology 2011, 74: 783-790. PMID: 21521263, PMCID: PMC3089671, DOI: 10.1111/j.1365-2265.2011.03991.x.Peer-Reviewed Original ResearchConceptsPlasma renin activityVitamin D receptorLow plasma renin activityDietary sodium balanceRenin-angiotensin systemRenin activityFok1 polymorphismSodium balanceVitamin D receptor gene polymorphismsD receptor gene polymorphismsPopulation of hypertensivesReceptor gene polymorphismsFok1 genotypeHyperPATH cohortD deficiencyMultivariable analysisNormotensive individualsVitamin DRenin expressionVDR geneCardiovascular diseaseD receptorHuman studiesGene polymorphismsT alleleEpistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population
Penrod NM, Poku KA, Vaughn D, Asselbergs FW, Brown NJ, Moore JH, Williams SM. Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population. PLOS ONE 2011, 6: e16639. PMID: 21304999, PMCID: PMC3031598, DOI: 10.1371/journal.pone.0016639.Peer-Reviewed Original ResearchConceptsEpistatic interactionsPAI-1 levelsRenin-angiotensin systemMultiple genetic effectsPathway-specific genesD polymorphismPAI-1Genetic architectureT-PASingle SNP analysisGenetic regulationCentral genesSpecific genesCardiovascular diseaseFibrinolytic systemSNP analysisGenetic effectsGenesCleavage of angiotensinogenPlasminogen activator inhibitor-1Plasma t-PAT-PA levelsTissue plasminogen activatorActivator inhibitor-1Enzyme cleavage
2008
Male–female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population
Schoenhard JA, Asselbergs FW, Poku KA, Stocki SA, Gordon S, Vaughan DE, Brown NJ, Moore JH, Williams SM. Male–female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. Human Genetics 2008, 124: 479-488. PMID: 18953568, PMCID: PMC2770717, DOI: 10.1007/s00439-008-0573-x.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1PAI-1 levelsTissue-type plasminogen activatorRenin polymorphismPAI-1 4G/5G polymorphismRenin-angiotensin systemDiastolic blood pressurePopulation-based sampleActivator inhibitor-1Large-scale population-based samplePAI-1 expressionBlood pressureTotal cholesterolThromboembolic diseasePlasma levelsRisk factorsCardiovascular diseaseD polymorphismMetabolic parametersG polymorphismFibrinolytic systemGene polymorphismsThrombus formationCaucasian subjectsGhanaian population
2004
Uric acid and the state of the intrarenal renin-angiotensin system in humans
Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney International 2004, 66: 1465-1470. PMID: 15458439, DOI: 10.1111/j.1523-1755.2004.00909.x.Peer-Reviewed Original ResearchConceptsIntrarenal renin-angiotensin systemRenin-angiotensin systemSerum uric acid concentrationBody mass indexHigh-density lipoproteinUric acid concentrationRenal vascular responsePlasma renin activityAng IIRPF responseExperimental hyperuricemiaBlood pressureVascular responsesUric acidRenal plasma flow responsePara-aminohippuric acid clearanceHigh sodium balanceIntrarenal RAS activityRenal vascular responsivenessExogenous angiotensin IISerum high-density lipoproteinSerum uric acidMultivariable regression analysisPlasma flow responseRenin activity
2003
Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives
Murphey LJ, Morrow JD, Sawathiparnich P, Williams GH, Vaughan DE, Brown NJ. Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. Free Radical Biology And Medicine 2003, 35: 711-718. PMID: 14583335, DOI: 10.1016/s0891-5849(03)00395-2.Peer-Reviewed Original ResearchConceptsF2-isoprostane concentrationsMean arterial pressurePlasma F2-isoprostane concentrationsAng II infusionAng IIII infusionOxidative stressF2-isoprostanesAcute Ang II infusionMin ANG IIPlasma renin activityHigh salt intakeLow salt intakeRenin-angiotensin systemLow sodium dietAngiotensin II increasesBody mass indexRenal plasma flowPlasma F2-isoprostanesHuman cardiovascular diseaseHuman hypertensivesHypertensive volunteersHypertensive groupHypertensive humansNormotensive group
2002
PAI-1 in human hypertension: relation to hypertensive groups*
Srikumar N, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups*. American Journal Of Hypertension 2002, 15: 683-690. PMID: 12160190, DOI: 10.1016/s0895-7061(02)02952-7.Peer-Reviewed Original ResearchConceptsPlasma renin activityPAI-1 levelsPlasminogen activator inhibitor type 1Hypertensive subjectsInsulin resistanceLow reninRenin activityHigher PAI-1 levelsDietary salt restrictionLow-salt dietRenin-angiotensin systemActivator inhibitor type 1Inhibitor type 1Aldosterone levelsHypertensive groupSalt restrictionSodium dietSodium restrictionSalt dietHuman hypertensionType 1AldoModulator groupsNonmodulatorsRenin
2000
Endogenous bradykinin and the renin and pressor responses to furosemide in humans.
Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. Journal Of Pharmacology And Experimental Therapeutics 2000, 295: 644-8. PMID: 11046100.Peer-Reviewed Original ResearchConceptsPlasma renin activityMean arterial pressureHoe 140Renin responseEndogenous bradykininRenin activityArterial pressureHeart rateBasal plasma renin activityRenin-angiotensin systemAngiotensin I/Blood pressure regulationCrossover design studyAcute furosemide treatmentRenin regulationSpecific bradykininDiuretic responseFurosemide administrationFurosemide treatmentACE inhibitionReceptor antagonistPressure regulationBradykininFurosemideHumans
1999
Role of Angiotensin II in Coagulation and Fibrinolysis
Brown N, Vaughan D. Role of Angiotensin II in Coagulation and Fibrinolysis. Heart Failure Reviews 1999, 3: 193-198. DOI: 10.1023/a:1009757416302.Peer-Reviewed Original ResearchAntithrombotic effectAngiotensin type 1 receptor antagonistType 1 receptor antagonistVascular fibrinolytic balanceRenin-angiotensin systemTissue plasminogen activatorHypertensive patientsInhibitor PAI-1Angiotensin IIFibrinolytic balanceReceptor antagonistVasculoprotective propertiesPlatelet functionEnzyme inhibitorsPAI-1Plasminogen activatorMultiple mechanismsFibrinolysisSubstantial evidenceRecent studiesAngiotensinPatientsProstanoidsAntagonist
1998
Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1
Brown N, Agirbasli M, Williams G, Litchfield W, Vaughan D. Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1. Hypertension 1998, 32: 965-971. PMID: 9856958, DOI: 10.1161/01.hyp.32.6.965.Peer-Reviewed Original ResearchMeSH KeywordsAdultAldosteroneAngiotensin-Converting Enzyme InhibitorsCatecholaminesCircadian RhythmCreatinineDiet, Sodium-RestrictedFibrinolysisHemodynamicsHumansHydrocortisoneIsoquinolinesMalePlasminogen Activator Inhibitor 1QuinaprilReninRenin-Angiotensin SystemSodiumSupine PositionTetrahydroisoquinolinesTissue Plasminogen ActivatorConceptsLow salt intakeRenin-angiotensin systemPAI-1 antigenPlasma renin activitySalt intakeACE inhibitionMyocardial infarctionTPA antigenFibrinolytic systemPAI-1Plasminogen activator inhibitor-1 activityTissue-type plasminogen activator antigenPAI-1 antigen concentrationsPAI-1 antigen levelsThrombotic cardiovascular eventsHigh salt intakeLeft ventricular dysfunctionRecurrent myocardial infarctionPlasminogen activator antigenInhibitor-1 activityPlasma PAI-1PAI-1 activityConcomitant ACE inhibitionCardiovascular eventsRenin activityEffect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects
Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects. New England Journal Of Medicine 1998, 339: 1285-1292. PMID: 9791144, DOI: 10.1056/nejm199810293391804.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBradykininBradykinin Receptor AntagonistsCaptoprilDiet, Sodium-RestrictedDrug InteractionsDrug Therapy, CombinationFemaleHumansHypertensionKidneyLosartanMaleReference ValuesRenin-Angiotensin SystemSingle-Blind MethodConceptsPlasma renin activityBlood pressureACE inhibitionHypertensive subjectsShort-term effectsRenin activitySpecific bradykinin receptor antagonistAngiotensin converting enzyme (ACE) inhibitorsAdministration of captoprilAdministration of losartanBradykinin receptor blockadeCoadministration of icatibantContribution of bradykininRenal hemodynamic responseNormal blood pressureRenin-angiotensin systemSeparate study daysBradykinin receptor antagonistDegradation of bradykininAntagonist losartanHypertensive personsHypotensive effectAngiotensin IIAngiotensin-ConvertingHemodynamic response
1997
Plasminogen actiwator inhibitor type 1 in diabetes and hypertension
Litchfield W, Brown N, Vaughan D. Plasminogen actiwator inhibitor type 1 in diabetes and hypertension. Current Opinion In Endocrinology Diabetes And Obesity 1997, 4: 233-238. DOI: 10.1097/00060793-199706000-00009.Peer-Reviewed Original ResearchCardiovascular riskPAI-1Inhibitor type 1Type 1Elevated levelsIncreased cardiovascular riskRenin-angiotensin systemEndogenous fibrinolytic systemPlasminogen activator inhibitor type 1Activator inhibitor type 1Tissue plasminogen activatorHypertensive patientsEssential hypertensionMyocardial infarctionCardiovascular diseaseFibrinolytic systemHypertensionPlasminogen activatorStrong associationIncidenceRiskPrimary inhibitorHyperinsulinemiaHypertriglyceridemiaInfarction
1996
The Renin-Angiotensin and Fibrinolytic Systems Co-Conspirators in the Pathogenesis of Ischemic Cardiovascular Disease
Brown N, Vaughan D. The Renin-Angiotensin and Fibrinolytic Systems Co-Conspirators in the Pathogenesis of Ischemic Cardiovascular Disease. Trends In Cardiovascular Medicine 1996, 6: 239-243. PMID: 21232303, DOI: 10.1016/s1050-1738(96)00091-6.Peer-Reviewed Original ResearchTissue-type plasminogen activatorFibrinolytic systemIschemic cardiovascular eventsRenin-angiotensin systemBreakdown of bradykininCardiovascular eventsAngiotensin IIT-PA secretionClinical observationsPotent stimulusStimulates releaseAngiotensin IPAI-1Plasminogen activatorVivo dataMajor inhibitorACEAngiotensinBradykininSecretionVasculatureAngiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy
Hunley T, Julian B, Phillips J, Summar M, Yoshida H, Horn R, Brown N, Fogo A, Ichikawa I, Kon V. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney International 1996, 49: 571-577. PMID: 8821846, DOI: 10.1038/ki.1996.81.Peer-Reviewed Original ResearchConceptsRenin-angiotensin systemIgA nephropathyRenal functionDD genotypeMyocardial infarctionCardiovascular diseaseACE genotype frequenciesGene polymorphismsBiopsy-proven IgA nephropathyACE I/D polymorphismAGT 235TEnzyme deletion polymorphismNormal serum creatinineRenal disease progressionACE DD genotypeEnzyme gene polymorphismGenotype frequenciesI gene polymorphismStable creatinineAngiotensin systemSerum creatinineRenal statusVentricular hypertrophyCaucasian patientsRisk factors
1991
A pharmacodynamic interaction between caffeine and phenylpropanolamine
Brown N, Ryder D, Branch R. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clinical Pharmacology & Therapeutics 1991, 50: 363-371. PMID: 1914371, DOI: 10.1038/clpt.1991.152.Peer-Reviewed Original ResearchConceptsBlood pressurePharmacodynamic interactionsPlasma renin activityRenin-angiotensin systemDrug-free subjectsCoadministration of caffeineRenin responseRenin activityPharmacokinetic interactionsCatecholamine levelsSupine positionNormal subjectsLatin square design studyDrug AdministrationRandom orderPhenylpropanolamineMetabolite levelsPlaceboCaffeineSubjectsAdditive increaseHoursCoadministrationEpinephrineAdministration